Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Which stocks have an unusual volume on Monday?

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Quoin Pharmaceuticals shares are trading higher Friday morning after the company announced a private placement financing of up to $104.5 million.

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Quoin Pharmaceuticals (QNRX) reported Q2 2025 EPS of -$6.28, beating estimates, but revenue was $0. Stock fell 5% pre-market despite positive clinical updates for QRX003 in Netherton Syndrome.

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Shares of Quoin Pharmaceuticals surged 47.5% Wednesday morning. The stock is higher following the release of promising initial data from its ongoing clinical study of QRX003.